带状疱疹疫苗临床研究进展

李娟; 李靖欣; 金鹏飞; 张宏秀; 朱凤才

doi:10.16462/j.cnki.zhjbkz.2019.11.022

带状疱疹疫苗临床研究进展

doi: 10.16462/j.cnki.zhjbkz.2019.11.022

李娟¹,
李靖欣²,
金鹏飞²,
张宏秀³,
朱凤才^{1, 4, ,}

1.
211166 南京, 南京医科大学公共卫生学院
2.
210009 南京, 江苏省疾病预防控制中心疫苗临床评价所
3.
210029 南京, 南京医科大学第一附属医院妇产科
4.
210009 南京, 江苏省疾病预防控制中心国家卫生健康委员会肠道病原微生物重点实验室, 南京医科大学全球健康中心

基金项目:

国家科技重大专项 2018ZX09734004

详细信息

通讯作者:
朱凤才, E-mail: jszfc@vip.sina.com

中图分类号: R181
计量
- 文章访问数: 537
- HTML全文浏览量: 179
- PDF下载量: 101
- 被引次数: 0
出版历程
- 收稿日期: 2019-05-15
- 修回日期: 2019-07-31
- 刊出日期: 2019-11-10

Progress in research of clinical trials of herpes zoster vaccines

1.
School of Public Health, Nanjing Medical University, Nanjing 211166, China
2.
Department of Vaccine Clinical Evaluation, Jiangsu Provincial Center for Disease Control and Prevention, Nanjing 210009, China
3.
Department of Obstetrics and Gynecology, The First Affliated Hospital of Nanjing Medical University, Nanjing 210029, China
4.
NHC Key laboratory of Enteric Pathogenic Microbiology, Jiangsu Provincial Center for Disease Control and Prevention; Center for Global Health, Nanjing Medical University, Nanjing 210009, China

Funds:

National Scientific and Technology Major Project 2018ZX09734004

More Information

Corresponding author: Zhu Feng-cai, E-mail: jszfc@vip.sina.com

摘要

摘要: 带状疱疹（herpes zoster，HZ）好发于中老年人，是由潜伏于感觉神经节的水痘-带状疱疹病毒（varicella-zoster virus，VZV）复发感染所致。近年由于种种原因，尤其是中国人口老龄化愈发严重使中国HZ发病率急剧上升。虽然HZ具有自限性，但其并发症会降低患者生活质量并加重患者家庭及社会的经济负担，为减少发病率、提升老年人的晚年生活质量，研发安全有效的HZ疫苗可能是一种重要而有效的措施。本文旨在对HZ疫苗临床研究进展作简要综述，为中国HZ疫苗的使用及带状疱疹疾病的防制工作提供参考。
- 带状疱疹 /
- 疫苗 /
- 临床试验 /
- 保护效力 /
- 安全性
Abstract: Herpes zoster (HZ) is more common in middle-aged and elderly people, and is caused by varicella-zoster virus (VZV) that is latent in sensory ganglia. In recent years, due to various reasons, especially the aging of China's population has become more serious, the incidence of HZ in China has risen sharply. Although HZ is self-limited, its complications will still reduce the quality of life of patients and increase the economic burden of patients' families and society. In order to reduce the incidence and improve the quality of life of the elderly in their later years, the development of safe and effective HZ vaccine may be an important and effective measure. This article aims to make a brief review of the progress in research for clinical trials of HZ vaccines, so as to provide a reference for the use of HZ vaccine and the prevention and control of HZ disease in China.
- Herpes zoster /
- Vaccine /
- Clinical trial /
- Protective efficacy /
- Safety

HTML全文

参考文献(33)

[1]	Gnann JW, Whitley RJ. Herpes Zoster[J]. N Engl J Med, 2002, 347(5): 340-346. DOI: 10.1056/NEJMcp013211.
[2]	Weitzman D, Shavit O, Stein M, et al. A population based study of the epidemiology of Herpes Zoster and its complications[J]. J Infect, 2013, 67(5): 463-469. DOI: 10.1016/j.jinf.2013.06.016.
[3]	Johnson RW, Bouhassira D, Kassianos G, et al. The impact of herpes zoster and post-herpetic neuralgia on quality-of-life[J]. BMC Med, 2010, 8(1): 37-40. DOI: 10.1186/1741-7015-8-37.
[4]	Kawai K, Gebremeskel BG, Acosta CJ. Systematic review of incidence and complications of herpes zoster: towards a global perspective[J]. BMJ open, 2014, 4(6): e004833. DOI: 10.1136/bmjopen-2014-004833.
[5]	Zhu Q, Zheng H, Qu H, et al. Epidemiology of herpes zoster among adults aged 50 and above in Guangdong, China[J]. Hum Vaccin Immunother, 2015, 11(8): 2113-2118. DOI: 10.1080/21645515.2015.1016672.
[6]	Giovanni G, Nicoletta V, Parvanè K, et al. Prevention of herpes zoster and its complications: from the clinic to the real-life experience with the vaccine[J]. J Med Microbiol, 2016, 65(12): 1363-1369. DOI: 10.1099/jmm.0.000386.
[7]	Weinberg A, Levin MJ. VZV T cell-mediated immunity[J]. Curr Top Microbiol Immunol, 2010, 342(1): 341. DOI: 10.1007/82_2010_31.
[8]	Chen SY, Suaya JA, Li Q, et al. Incidence of herpes zoster in patients with altered immune function[J]. Infection, 2014, 42(2): 325-334. DOI: 10.1007/s15010-013-0550-8.
[9]	Yun H, Yang S, Chen L, et al. Risk of herpes zoster in auto-immune and inflammatory diseases: implications for vaccination[J]. Arthritis Rheumatol, 2016, 68(9): 2328-2337. DOI: 10.1002/art.39670.
[10]	Grabar S, Tattevin P, Selinger-Leneman H, et al. Incidence of herpes zoster in HIV-infected adults in the combined antiretroviral therapy era: results from the FHDH-ANRS CO4 cohort[J]. Clin Infect Dis, 2015, 60(8): 1269-1277. DOI: 10.1093/cid/ciu1161.
[11]	Seo HM, Kim YS, Bang CH, et al. Antiviral prophylaxis for preventing herpes zoster in hematopoietic stem cell transplant recipients: A systematic review and meta-analysis[J]. Antiviral Res, 2017, 140(Complete): 106-115. DOI: 10.1016/j.antiviral.2017.01.011.
[12]	Kawai K, Yawn BP. Risk factors for herpes zoster: a systematic review and meta-analysis[J]. Mayo Clin Proc, 2017, 92(12): 1806-1821. DOI: 10.1016/j.mayocp.2017.10.009.
[13]	Mcdonald EM, De Kock J, Sf Ram F. Antivirals for management of herpes zoster including ophthalmicus: a systematic review of high-quality randomized controlled trials[J]. Antivir Ther, 2011, 17(2): 255-264. DOI: 10.3851/imp2011.
[14]	Oxman MN, Levin MJ, Johnson GR, et al. A vaccine to prevent herpes zoster and postherpetic neuralgia in older adults[J]. N Engl J Med, 2005, 352(22): 2271-2284. DOI: 10.1056/NEJMoa051016.
[15]	Levin MJ, Oxman MN, Zhang JH, et al. Varicella-zoster virus-specific immune responses in elderly recipients of a herpes zoster vaccine[J]. J Infect Dis, 2008, 197(6): 825-835. DOI: 10.1086/528696.
[16]	Harpaz R, Ortega-Sanchez IR, Seward JF. Prevention of herpes zoster: recommendations of the Advisory Committee on Immunization Practices (ACIP)[J]. Mmwr Recomm Rep, 2008, 57(RR-5): 1-30.
[17]	Schmader KE, Levin MJ, Gnann JW, et al. Efficacy, safety, and tolerability of herpes zoster vaccine in persons aged 50-59 years[J]. Clin Infect Dis, 2012, 54(7): 922-928. DOI: 10.1093/cid/cir970.
[18]	Katz SL. Varicella and herpes zoster vaccines: WHO position paper, June 2014[J]. Wkly Epidemiol Rec, 2014, 89(25): 265-287. PMID: 24983077.
[19]	Willis ED, Woodward M, Brown E, et al. Herpes zoster vaccine live: a 10 year review of post-marketing safety experience[J]. Vaccine, 2017, 35(52): 7231-7239. DOI: 10.1016/j.vaccine.2017.11.013.
[20]	Lecrenier N, Beukelaers P, Colindres R, et al. Development of adjuvanted recombinant zoster vaccine and its implications for shingles prevention[J]. Expert Rev Vaccines, 2018, 17(7): 619-634. DOI: 10.1080/14760584.2018.1495565.
[21]	Didierlaurent AM, Laupèze B, Di PA, et al. Adjuvant system AS01: helping to overcome the challenges of modern vaccines[J]. Expert Rev Vaccines, 2017, 16(1): 55-63. DOI: 10.1080/14760584.2016.1213632.
[22]	Himal L, Cunningham AL, Olivier G, et al. Efficacy of an adjuvanted herpes zoster subunit vaccine in older adults[J]. N Engl J Med, 2015, 372(22): 2087-2096. DOI: 10.1056/NEJMoa1501184.
[23]	Cunningham AL, Lal H, Kovac M, et al. Efficacy of the herpes zoster subunit vaccine in adults 70 years of age or older[J]. N Engl J Med, 2016, 375(11): 1019-1032. DOI: 10.1056/NEJMoa1603800.
[24]	Schwarz TF, Aggarwal N, Moeckesch B, et al. Immunogenicity and safety of an adjuvanted herpes zoster subunit vaccine coadministered with seasonal influenza vaccine in adults aged 50 years or older[J]. J Infect Dis, 2017, 216(11): 1352-1361. DOI: 10.1093/infdis/jix481.
[25]	Maréchal C, Lal H, Poder A, et al. Immunogenicity and safety of the adjuvanted recombinant zoster vaccine co-administered with the 23-valent pneumococcal polysaccharide vaccine in adults ≥ 50 years of age: a randomized trial[J]. Vaccine, 2018, 36(29): 4278-4286. DOI: 10.1016/j.vaccine.2018.05.110.
[26]	Dooling KL, Guo A, Patel M, et al. Recommendations of the Advisory Committee on Immunization Practices for use of herpes zoster vaccines[J]. Am J Transplant, 2018, 18(3): 756-762. DOI: 10.1111/ajt.14683.
[27]	Levin MJ. Use of varicella vaccines to prevent herpes zoster in older individuals[J]. Arch Virol, 2001, 17(17): 151-160. DOI: 10.1007/978-3-7091-6259-0_16.
[28]	Sperber SJ, Smith BV, Hayden FG. Serologic response and reactogenicity to booster immunization of healthy seropositive adults with live or inactivated varicella vaccine[J]. Antiviral Res, 1992, 17(3): 213-222. DOI: 10.1016/0166-3542(92)90042-4.
[29]	Masahiro K, Song-Wong K, Yoichi T. Varicella vaccine in recipients of hematopoietic-cell transplants[J]. N Engl J Med, 2002, 347(20): 1624-1625. DOI: 10.1056/NEJM200211143472017.
[30]	Mullane KM, Winston DJ, Wertheim MS, et al. Safety and immunogenicity of heat-treated zoster vaccine (ZVHT) in immunocompromised adults[J]. J Infect Dis, 2013, 208(9): 1375-1385. DOI: 10.1093/infdis/jit344.
[31]	Winston DJ, Mullane KM, Cornely OA, et al. Inactivated varicella zoster vaccine in autologous haemopoietic stem-cell transplant recipients: an international, multicentre, randomised, double-blind, placebo-controlled trial[J]. Lancet, 2018, 391(10135): 2116-2127. DOI: 10.1016/S0140-6736(18)30631-7.
[32]	Schmidt-Chanasit J, Sauerbrei A. Evolution and world-wide distribution of varicella-zoster virus clades[J]. Infect Genet Evol, 2011, 11(1): 1-10. DOI: 10.1016/j.meegid.2010.08.014.
[33]	Adriana W, Zhang JH, Oxman MN, et al. Varicella-zoster virus-specific immune responses to herpes zoster in elderly participants in a trial of a clinically effective zoster vaccine[J]. J Infect Dis, 2009, 200(7): 1068-1077. DOI: 10.1086/605611.